Background: Real-world evidence is sparse on the benefits of allergen immunother-
| INTRODUCTION
Allergic rhinitis (AR) is a common inflammatory condition associated with bothersome symptoms affecting the upper airways, nose and eyes.
1,2 AR affects up to 40% of the population worldwide, including 23%-30% of people within Europe. 3 Birch pollen is among the top three most-diagnosed allergens responsible for respiratory allergies, 4 and birch is considered to be the major pollen-allergen-producing tree in northern Europe, 5 inducing mostly nasal symptoms. 6 AR represents a considerable burden on public health, impacting daily activities, quality of life and productivity. 1 It is also frequently associated with various comorbidities, including asthma. 1,7-10 AR often precedes asthma, [11] [12] [13] with the progression from AR to asthma considered part of the "allergic march", 14 while uncontrolled AR may be associated with worsening of coexisting asthma. 15 Allergen immunotherapy (AIT), in the form of subcutaneous or sublingual immunotherapy (SCIT/SLIT), is the only treatment for AR and/or allergic asthma (AA) with long-term efficacy. [16] [17] [18] [19] In randomized, double-blind, placebo-controlled studies, precoseasonal administration of birch pollen SLIT for 2 years led to a significant and sustained reduction in symptoms and symptomatic medication use in patients with birch pollen-associated allergic rhinoconjunctivitis (ARC) 5 and patients with AR plus asthma. 20 However, long-term data from the real-world setting, assessing the preventative role of different AIT preparations on AR and/or AA progression, are sparse. 5, [20] [21] [22] [23] [24] Real-world studies are particularly valuable because they can allow for longer observation periods and larger, more heterogeneous patient cohorts than clinical trials.
There is ongoing debate on which, if any, is more effective in AIT: native or modified allergen extracts, and SCIT or SLIT. It was recently suggested that native preparations might be more effective 25 ; on the other hand, modified preparations are usually associated with a lower side-effect rate. 26, 27 Therefore, in the present analysis, we compared in a real-life situation the effectiveness of 6 different birch or three-tree (birch, 
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G R A P H I C A L A B S T R A C T
In this retrospective, real-world study in Germany, birch pollen allergen immunotherapy (AIT) demonstrated significant benefits up to 6 years post-treatment in patients with birch pollen-associated allergic rhinitis (AR) and/or asthma. AIT was associated with significantly improved AR and asthma symptoms as the medication dispensing decreased; nearly two-thirds and one-half of patients initially using AR or asthma medications, respectively, no longer required them at study end. During the period in which they were receiving AIT, patients with AR but not asthma had a significantly decreased risk of new-onset asthma medication dispensing. 
| Analytical time periods
For the AIT group, index date was defined as date of first prescription of one of the selected AIT products. For the control group, index date was defined as date of the second of three relevant prescriptions in three consecutive three-tree pollen seasons. This had to be in the same index seasonal cycle as the index date of the individual product patient matched to the corresponding control patient.
The pre-index period was defined as the 365 days before index date, and the treatment period was from index date of the first AIT product to expiry date of the last prescription of this product. The follow-up period was from end of the treatment period to end of study, and the full-analysis period combined the treatment and follow-up periods. were actually prescribed for birch/three-tree pollen allergy, it was also required that at least the identifying prescriptions were dispensed during the three-tree pollen season (February to May) or the month before it (January).
| Study endpoints
Study endpoints and primary analyses included: (1) AR progression from 2 to 6 years after active treatment cessation in patients with AR (± asthma) at baseline; (2) occurrence and time to development of asthma in patients with AR without associated asthma at baseline, during treatment and from 2 to 6 years post-treatment; and (3) asthma progression from 2 to 6 years after active treatment cessation in patients with asthma (± AR) at baseline. Secondary analyses duplicated the primary analyses, but with the AIT group split into 6 individual AIT product subgroups, and the non-AIT control group acting as the reference for comparisons.
| Statistical analysis
Descriptive statistics were presented for all outcome variables and covariates, split by grouped or individual products (ie, overall AIT, non-AIT control, natural SLIT, natural SCIT and four individual allergoid SCIT formulations). Analyses of medication intake progression (AR or asthma) were carried out by regression using a general linear model, with the ratio of annual number of prescriptions in the analysis period vs the pre-index period used as the outcome variable.
Analysis of asthma medication intake as a Y/N variable was achieved by logistic regression. Because the probability of asthma medication intake occurrence would also depend on length of analytical time span, the individual length of this period was included as a covariate.
Time to asthma medication intake was investigated using survival analysis. The proportion of patients with any level of treatment between the AIT and non-AIT control groups was also analysed by logistic regression. Statistical analyses were based on two-way testing without exception. For all statistical tests, significance level was set to 5% (P < 0.05). Analyses were performed using SAS 9.4 software SAS Institute, Inc., Cary, NC, USA.
| RESULTS
In total, 9001 AIT patients and 45 005 matched non-AIT control patients were included, and their demographic and prescriptionrelated characteristics at index are shown in Table 1 . The majority of patients (~85% for both AIT and non-AIT groups) underwent ≤3 seasonal cycles of treatment (Table 2) , and only 14.8% of AIT patients were treated for longer. The follow-up period was slightly longer for T A B L E 1 Demographic and prescription-related characteristics of patients in the AIT (overall and by product) and non-AIT groups at index date or during the pre-index period 
Allergoid SCIT 2 1120
Allergoid SCIT 3 630
Allergoid SCIT 4 607

Natural SCIT 755
Natural SLIT 634 n F I G U R E 3 Odds of starting asthma medication use during the treatment (A), post-treatment (B) or full-analysis (C) periods in patients with birch family pollenassociated AR but no concomitant asthma at baseline. AIT, allergen immunotherapy; CI, confidence interval; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy the low proportion of patients aged <18 years in the study (the ability of AIT to prevent asthma appears to be greatest in children 29 ).
These findings are in contrast to those in a previous grass pollen SLIT study, 21 in which a sustained beneficial effect of SLIT on lowering new-onset asthma risk was noted in the post-treatment period.
However, the grass pollen SLIT study included a much higher proportion of children in the AIT group than did the present study (~50% vs~20%, respectively).
The present real-world findings add to the current body of clinical evidence demonstrating the benefits of AIT in patients with birch pollen-associated AR. In a randomized, double-blind, placebocontrolled Phase IIIb study in patients with birch-associated ARC (N = 574), treatment for two consecutive pre-and coseasonal periods with birch pollen SLIT was associated with a sustained reduction in symptoms and medication use, measured with the Average Adjusted Symptom Score. 5 In a randomized, double-blind, placebocontrolled study of birch pollen SLIT administered using a precoseasonal protocol repeated for 2 years in patients presenting with severe rhinitis and slight to moderate asthma (N = 24), median number of days with asthma at visit 3 was 10 vs 13 in the SLIT and placebo groups, respectively, and at visit 6 was 2 vs 7, respectively (P < 0.05 between groups). A reduction in asthma medication intake occurred in 77% of actively treated vs 0% of placebo-treated patients (P = 0.05). The current study used an improved patient-matching process, compared with the aforementioned grass pollen SLIT LRx database analysis. 21, 24 Patients were stratified into AIT or non-AIT groups and matched by index year, age group, gender, main indication (AR/AA) at index date, number of seasonal cycles while on treatment and baseline AR/AA treatment prescriptions. This reduced confounding and wide differences in covariate distribution helped align groups by treatment-period duration and avoided possible bias from intergroup differences in baseline treatment levels. All AIT patients satisfying inclusion/exclusion criteria were analysed and then matched 1:5 with non-AIT patients; therefore, the covariate distributions observed reflect those of the overall AIT group, but may differ significantly from those of the general non-AIT patient population before matching.
The high proportion of patients with unknown gender reflects German practice in not recording gender information on prescriptions. Instead, this was deduced/inferred from the first name of the patient, and in cases of ambiguity, patients were recorded as having "unknown" gender. Nevertheless, where known, the gender distribution was consistently and notably skewed towards female in the AIT group. It is unclear whether this reflects a genuine clinically relevant, increased sensitivity of females to birch family pollen or just an artefact of the selection process, because a study conducted in children and adolescents in Germany reported a higher sensitization to birch pollen among boys than girls. Hartmut Richter http://orcid.org/0000-0002-2853-6427
